Coronavirus Vaccine: Oxford vaccine can be 90% effective, results show | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Tuesday
January 31, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
TUESDAY, JANUARY 31, 2023
Oxford vaccine can be 90% effective, results show

Coronavirus chronicle

Reuters
23 November, 2020, 01:10 pm
Last modified: 23 November, 2020, 10:33 pm

Related News

  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • Children aged 5-11 to get Covid jabs from 11 August
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap

Oxford vaccine can be 90% effective, results show

The Oxford jab is far cheaper, and is easier to store and get to every corner of the world than the other two

Reuters
23 November, 2020, 01:10 pm
Last modified: 23 November, 2020, 10:33 pm
Britain's Medicines and Healthcare products Regulatory Agency (MHRA) started an accelerated "rolling review" of the vaccine at the start of this month as data comes in on safety and efficacy. Photo: Reuters
Britain's Medicines and Healthcare products Regulatory Agency (MHRA) started an accelerated "rolling review" of the vaccine at the start of this month as data comes in on safety and efficacy. Photo: Reuters

Britain's AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects, giving the world another important tool to halt the Covid-19 pandemic.

The vaccine developed by Oxford University was 90% effective in preventing Covid-19 when it was administered as a half dose followed by a full dose at least one month apart, according to data from the late-stage trials in Britain and Brazil.

No serious safety events related to the vaccine have been confirmed and it was well tolerated across both dosing regimens, it said.

"This vaccine's efficacy and safety confirm that it will be highly effective against Covid-19 and will have an immediate impact on this public health emergency," Pascal Soriot, Astra's chief executive, said in a statement.

AstraZeneca will have 200 million doses by the end of 2020, with 700 million doses ready globally by the end of the first quarter of 2021, operations executive Pam Cheng said on Monday.

The vaccine's effectiveness depended on the dosing, and fell to just 62% when given as two full doses rather than a half-dose first. But scientists cautioned against seeing this as evidence that it would be less useful than rival vaccines from Pfizer and Moderna, which each prevented about 95% of cases according to interim data from their late-stage trials.

"I think it is a real fool's errand to start trying to pick these three (Pfizer/Moderna/Astra) apart on the basis of snippets of phase 3 data from press releases," said Danny Altmann, professor of immunology at Imperial College London.

"For the bigger picture, my suspicion is that by the time we are a year down the line, we'll be using all three vaccines with about 90% protection - and we'll be a lot happier."

Scientists also noted there may be advantages to AstraZeneca's vaccine.

"100 million doses by january," says Adar Poonawalla on oxford vaccine

"Importantly, from what we have heard the vaccine seems to prevent infection not just disease. This is important as the vaccine could reduce the spread of the virus as well as protect the vulnerable from severe disease," said Peter Horby, a professor of emerging infectious diseases and global health at the University of Oxford,

AstraZeneca's vaccine can also be distributed more easily because it can be kept at refrigerator temperature, unlike the drugs from Pfizer and Moderna which have to be stored frozen. That would make the AstraZeneca shot easier to transport and store globally, particularly in lower and middle-income countries.

'INCREDIBLY EXCITING'

The British drugmaker's preliminary trial results mark a fresh breakthrough in the fight against a pandemic that has killed nearly 1.4 million people and roiled the global economy.

Britain is among countries that pre-bought large quantities of the new vaccine. Officials said its success means normal life can return sooner. It was "incredibly exciting news the Oxford vaccine has proved so effective in trials," said Prime Minister Boris Johnson.

There would be 20 million doses in Britain by the end of the year, with 70 million doses for the UK by the end of Q1 2021.

Shares and oil prices rose as investors bet the rollout of another vaccine would revive the global economy next year even as virus case numbers surge.

The STOXX index of Europe's 600 largest shares rose 0.5% to its highest since February but AstraZeneca shares fell more than 2% as traders perceived the efficacy data as disappointing compared with rivals.

The interim analysis was based on 131 infections among participants who received the vaccine and those in a control group who were given an established meningitis shot.

Public health experts say the world will need many vaccines to meet global demand.

The AstraZeneca vaccine uses a modified version of a chimpanzee common cold virus to deliver instructions to cells to fight the target virus, a different approach from the new technology known as messenger RNA (mRNA) deployed by Pfizer/BioNTech and Moderna.

AstraZeneca, one of Britain's most valuable listed companies, will now immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval.

It will also seek an emergency use listing from the World Health Organization to speed up availability in low-income countries. In parallel, the full analysis of the interim results is being submitted for publication in a peer-reviewed journal.

Top News / World+Biz

Oxford University vaccine / Coronavirus Vaccine / AstraZeneca Covid-19 Vaccine / Oxford-AstraZeneca / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
    IMF approves Bangladesh's $4.5 billion loan proposal
  • Despite downturn 3 dozen listed firms plan Tk7,500cr investment
    Despite downturn 3 dozen listed firms plan Tk7,500cr investment
  • Mysterious resignation of SIBL chairman, addl MD
    Mysterious resignation of SIBL chairman, addl MD

MOST VIEWED

  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  •  A medical worker checks the IV drip treatment of a patient lying on a bed in the emergency department of a hospital, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China, January 5, 2023. REUTERS/Staff
    China says Covid deaths down by nearly 80 percent

Related News

  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • Children aged 5-11 to get Covid jabs from 11 August
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap

Features

Photo: Courtesy

The Hawkers: Where minimalism meets motifs

18h | Brands
TBS illustration

Where do Shariah-compliant mutual funds stand in Bangladesh

17h | Panorama
Sketch: TBS

A subsidy war without winners

17h | Panorama
Photo: Collected

Oppo Reno 8T first look revealed!

18h | Brands

More Videos from TBS

two more factories of the country got platinum certificate.

two more factories of the country got platinum certificate.

9h | TBS Today
Iconic villains of Bollywood

Iconic villains of Bollywood

10h | TBS Entertainment
General knowledge "Gravity"

General knowledge "Gravity"

8h | Videos
Will tanks turn the tide for Ukraine?

Will tanks turn the tide for Ukraine?

9h | TBS World

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

3
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

4
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

5
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]